Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5126 | 329042-31-1 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Fish oil-derived free fatty acids including multiple omega-3 fatty acids, eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] being the most abundant. The mechanism of action of omega-3-carboxylic acids is not completely understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal beta-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Omega-3-carboxylic acids may reduce the synthesis of triglycerides in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 5, 2014 | FDA | ASTRAZENECA PHARMS |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| FDA CS | M0023885 | Fatty Acids, Omega-3 |
| FDA EPC | N0000175583 | Omega-3 Fatty Acid |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertriglyceridemia | indication | 302870006 |
None
None
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS | EPANOVA | ASTRAZENECA | N205060 | May 5, 2014 | DISCN | CAPSULE | ORAL | 10117844 | Jan. 4, 2033 | TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET |
| 1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS | EPANOVA | ASTRAZENECA | N205060 | May 5, 2014 | DISCN | CAPSULE | ORAL | 9050308 | Jan. 4, 2033 | TREATMENT OF HYPERTRIGLYCERIDEMIA |
None
None
| ID | Source |
|---|---|
| CHEBI:755156 | CHEBI |
| CHEMBL3137327 | ChEMBL_ID |
| DB09568 | DRUGBANK_ID |
| 1652071 | RXNORM |
| 234233 | MMSL |
| 015520 | NDDF |
| C3832882 | UMLSCUI |
| 76322221 | PUBCHEM_CID |
| F85N2YHE4E | UNII |
| C000708078 | MESH_SUPPLEMENTAL_RECORD_UI |
None